Compare Adaptive Biotechnologies Corp (ADPT) vs Procter & Gamble Co (PG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Procter & Gamble Co — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Procter & Gamble Co trades at $148.99 (market cap $355.69B). The key difference: Procter & Gamble Co is far larger — about 106.8× Adaptive Biotechnologies Corp's market cap, and Procter & Gamble Co pays a 2.79% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | PG | |
|---|---|---|
Market Cap | $3.33B | $355.69B |
Sector | Health | Consumer Staples |
52-Week High | $22.37 | $167.18 |
52-Week Low | $10.24 | $138.10 |
Enterprise Value | $3.19B | $381.17B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Procter & Gamble (PG) trades at $149.83, up 0.35% today, with a bullish technical signal from moving averages and ADX indicators. The company maintains strong profitability with a 19.16% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights include a new WNBA partnership and ongoing supply chain improvements, while analyst consensus remains positive with a $159.88 price target.
PG offers stable growth and reliable dividends, supported by consistent cash flow and 69 years of dividend increases. Risks include premium valuation multiples and modest revenue growth outlook. The stock presents a defensive investment opportunity amid market volatility, with upside potential aligned with analyst targets but sensitivity to consumer demand fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
